Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 12Terminated 3Recruiting 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Rhabdoid Tumor 1Recurrence 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Multiple Myeloma 1Medulloblastoma 1Glioma 1Ependymoma 1Choroid Plexus Carcinoma 1Brain Neoplasms 1

Interventions

Dexamethasone 45Bortezomib 19Lenalidomide 18Calcium Dobesilate 18Melphalan 16Cyclophosphamide 11pomalidomide 10daratumumab 9elotuzumab 8carfilzomib 8pembrolizumab 6ixazomib 6fludarabine phosphate 6dexamethasone acetate 6fludarabine 5dexamethasone 21-phosphate 5Filgrastim 5venetoclax 4selinexor 4auricularum 4Thalidomide 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4liposomal doxorubicin 3Whole-Body Irradiation 3Vorinostat 3Nivolumab 3Mycophenolic Acid 3Leukapheresis 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Multiple Myeloma × thymoglobulin × Clear all
NCT00995059 2023-01-05

Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma

Mayo Clinic

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡